Articles
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial

https://doi.org/10.1016/S1473-3099(12)70037-3Get rights and content

Summary

Background

Daily suppression of herpes simplex virus type 2 (HSV-2) reduces plasma HIV-1 concentrations and modestly delayed HIV-1 disease progression in one clinical trial. We investigated the effect of daily suppressive aciclovir on HIV-1 disease progression in Rakai, Uganda.

Methods

We did a single site, parallel, randomised, controlled trial of HIV-1, HSV-2 dually infected adults with CD4 cell counts of 300–400 cells per μL. We excluded individuals who had an AIDS-defining illness or active genital ulcer disease, and those that were taking antiretroviral therapy. Participants were randomly assigned (1:1) with computer-generated random numbers in blocks of four to receive either aciclovir 400 mg orally twice daily or placebo; participants were followed up for 24 months. All study staff and participants were masked to treatment, except for the two statisticians. The primary outcome was CD4 cell count less than 250 cells per μL or initiation of antiretroviral therapy for WHO stage 4 disease. Our intention-to-treat analysis used Cox proportional hazards models, adjusting for baseline log10 viral load, CD4 cell count, sex, and age to assess the risk of disease progression. We also investigated the effect of suppressive HSV-2 treatment stratified by baseline HIV viral load with a Cox proportional hazards model. This trial is registered with ClinicalTrials.gov, number NCT00405821.

Findings

440 participants were randomly assigned, 220 to each group. 110 participants in the placebo group and 95 participants in the treatment group reached the primary endpoint (adjusted hazard ratio [HR] 0·75, 95% CI 0·58–0·99; p=0·040). 24 participants in the placebo group and 22 in the treatment group were censored, but all contributed data for the final analysis. In a subanalysis stratified by baseline HIV viral load, participants with a baseline viral load of 50 000 copies mL or more in the treatment group had a reduced HIV disease progression compared with those in the placebo group (0·62, 0·43–0·96; p=0·03). No significant difference in HIV disease progression existed between participants in the treatment group and those in the placebo group who had baseline HIV viral loads of less than 50 000 copies per mL (0·90, 0·54–1·5; p=0·688). No safety issues related to aciclovir treatment were identified.

Interpretation

Aciclovir reduces the rate of disease progression, with the greatest effect in individuals with a high baseline viral load. Suppressive aciclovir might be warranted for individuals dually infected with HSV-2 and HIV-1 with viral loads of 50 000 copies per mL or more before initiation of antiretroviral treatment.

Funding

National Institute of Allergy and Infectious Diseases, National Cancer Institute (National Institutes of Health, USA).

Introduction

Interventions that slow HIV-1 disease progression could postpone the need for antiretroviral therapy and extend life expectancy of HIV-infected people, thus safe, effective, and low cost approaches to delay HIV disease progression are urgently needed. Despite the success achieved in scaling up antiretroviral therapy, most people infected with HIV-1 in low-income and middle-income countries are not yet taking antiretroviral therapy, because either they do not meet current criteria, or they do not have access. With many programmes facing funding constraints, cost-effective measures to delay initiation of antiretroviral therapy are needed.

Herpes simplex virus type 2 (HSV-2) has been shown to upregulate HIV-1 replication at the cellular level and to increase HIV-1 viral load.1 HSV-2 is the commonest cause of genital ulcer disease; seroprevalence of HSV-2 in HIV-1 infected individuals ranges from 70% to more than 90%.2, 3 Genital ulcer disease is prevalent in HIV-infected individuals and increases the risk of HIV transmission to uninfected partners.4 Reactivation of HSV-2 is common in people with HIV-1 and plasma and genital HIV-1 concentrations increase during reactivation.3, 5, 6, 7 HIV-1 viral load in plasma is the key determinant of HIV progression and transmission.8, 9 A meta-analysis of seven randomised trials of daily herpes suppressive therapy with aciclovir or valaciclovir for 8–12 weeks showed a 0·33 log10 copies per mL reduction in median plasma HIV-1 RNA concentration and one randomised controlled trial has shown a modest (16%) reduced risk of HIV disease progression in patients taking daily aciclovir.10, 11 We did a trial of aciclovir 400 mg twice daily to assess the effect on HIV disease progression in individuals in Uganda infected with HIV and HSV-2 who were not yet eligible for antiretroviral therapy.

Section snippets

Participants and study design

Eligible HIV-1, HSV-2 co-infected individuals aged 18 years and older from Rakai Health Sciences Program and affiliated HIV care programmes in the area were recruited between May 2007, and November 2008. Inclusion criteria were seropositivity for HIV-1 and HSV-2, and a CD4 cell count between 300 and 400 cells per μL. We excluded individuals with AIDS-defining illnesses, and individuals receiving antiretroviral therapy. All participants provided written informed consent. The study was approved

Results

Figure 1 shows the trial profile. 1404 potential participants were assessed for HSV-2, of whom 1236 (88%) were HSV-2 seropositive, 989 (80%) of whom were screened sequentially for enrolment up to the time of full enrolment. The major screening criterion that precluded enrolment was CD4 cell count outside the eligible range. Of the 504 participants deemed ineligible because of CD4 cell count, the high (n=290) and low (n=214) median CD4 cell counts per μL were 475 (IQR 434–549) and 248 (219–276)

Discussion

Aciclovir 400 mg twice daily for suppression of HSV-2 in HIV-1 co-infected individuals reduced the risk of HIV-1 disease progression by 25%. Ours is the second study with a disease progression endpoint (panel) and this result is similar although larger than the 16% reduction in the Partners in Prevention HSV/HIV Transmission study.10 This difference might be because of differences in enrolment criteria; CD4 cell counts between 300 and 400 cells per μL in this study, whereas the Partners study

References (29)

  • D Serwadda et al.

    Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda

    J Infect Dis

    (2003)
  • RS McClelland et al.

    Association between cervical shedding of herpes simplex virus and HIV-1

    AIDS

    (2002)
  • L Mole et al.

    The impact of active herpes simplex virus infection on human immunodeficiency virus load

    J Infect Dis

    (1997)
  • T Schacker et al.

    Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men

    JAMA

    (1998)
  • Cited by (35)

    View all citing articles on Scopus
    View full text